The market dynamics for Vitiligo are witnessing steady growth driven by increasing disease awareness, rising diagnosis rates, growing acceptance of targeted immunotherapies, and expanding treatment options for non-segmental vitiligo. Additionally,
Vitiligo Market is Projected to Witness Significant Growth by 2036 Owing to the Expansion of Targeted JAK Inhibitors and Emerging Immunomodulatory Therapies | DelveInsight
The market dynamics for Facioscapulohumeral Muscular Dystrophy are witnessing steady growth driven by increasing disease awareness, improving genetic diagnosis, growing investment in rare neuromuscular disorders, and the advancement of innovative
The Pompe Disease market is growing due to expanding newborn screening, improved diagnosis of infantile- and late-onset cases, increasing adoption of advanced enzyme replacement therapies, and rising gene therapy investments.
The Key Degenerative Disc Disease Companies in the market include – Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 40+ key companies continuously working towards
The Key Myasthenia Gravis Companies in the market include – Alexion, AstraZeneca, Argenx, Novartis, Alpine Immune Science, Toleranzia, Cabaletta Bio,
DelveInsight’s “JAK Inhibitor Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the JAK
DelveInsight’s “Glioblastoma Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape.
DelveInsight’s “ESCLC Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the ESCLC pipeline
DelveInsight’s, “RNA Interference Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA
